In another study conducted during the rituximab era, a decrease in relapse-free survival (RFS) and OS was observed in patients affected by B-cell NHL and B-lineage related AID; moreover, AID was associated with a poorer OS and RFS in DLBCL [8]. This evidence concerns the gene AICDA and B-cell non-Hodgkin lymphoma.